Regulus Therapeutics (RGLS) vs. MediciNova (MNOV) Head to Head Contrast

Regulus Therapeutics (NASDAQ: RGLS) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a summary of recent recommendations and price targets for Regulus Therapeutics and MediciNova, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regulus Therapeutics 0 3 2 0 2.40
MediciNova 0 0 1 0 3.00

Regulus Therapeutics presently has a consensus price target of $2.38, indicating a potential upside of 189.63%. Given Regulus Therapeutics’ higher probable upside, equities analysts plainly believe Regulus Therapeutics is more favorable than MediciNova.

Profitability

This table compares Regulus Therapeutics and MediciNova’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Regulus Therapeutics -99,868.07% -201.84% -92.58%
MediciNova N/A -32.09% -28.09%

Volatility and Risk

Regulus Therapeutics has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.

Institutional and Insider Ownership

53.7% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 18.8% of MediciNova shares are owned by institutional investors. 4.8% of Regulus Therapeutics shares are owned by insiders. Comparatively, 15.2% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Regulus Therapeutics and MediciNova’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regulus Therapeutics $70,000.00 1,217.82 -$71.90 million ($1.11) -0.74
MediciNova N/A N/A -$11.16 million ($0.32) -38.78

MediciNova has lower revenue, but higher earnings than Regulus Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

MediciNova beats Regulus Therapeutics on 7 of the 13 factors compared between the two stocks.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. The company has strategic alliance with AstraZeneca AB and Sanofi to discover, develop, and commercialize microRNA therapeutics; and Biogen Inc. on microRNA biomarkers for multiple sclerosis, as well as a clinical trial collaboration agreement with GSK LLC. It also has an oligonucleotide synthesis collaboration agreement with STA Pharmaceutical Co., Ltd. for research and mid-scale non-GMP/cGMP manufacturing. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

MediciNova Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Morgan Stanley Cuts Diana Shipping  Price Target to $4.00
Morgan Stanley Cuts Diana Shipping Price Target to $4.00
Diamond Offshore Drilling  PT Lowered to $14.00 at Bank of America
Diamond Offshore Drilling PT Lowered to $14.00 at Bank of America
Saba Closed-End Funds ETF  Announces $0.14 Monthly Dividend
Saba Closed-End Funds ETF Announces $0.14 Monthly Dividend
Flaherty & Crumrine  Declares Monthly Dividend of $0.08
Flaherty & Crumrine Declares Monthly Dividend of $0.08
FuzzBalls  Trading 41.9% Higher  Over Last Week
FuzzBalls Trading 41.9% Higher Over Last Week
First Trust NASDAQ US Multi-Asset Diversified Income Index Fun Plans Monthly Dividend of $0.05
First Trust NASDAQ US Multi-Asset Diversified Income Index Fun Plans Monthly Dividend of $0.05


© 2006-2018 Ticker Report. Google+.